

# REACT-CIPN: a study to assess the feasibility of a behavioural intervention for chemotherapy-induced peripheral neuropathy

<b>Submission date</b> 20/06/2023	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 26/06/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 11/02/2025	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

The REACT-CIPN study is focused on determining the feasibility of a randomized controlled trial (RCT) that investigates an intervention to alleviate the symptoms of chemotherapy-induced peripheral neuropathy (CIPN). In this study, participants are randomly assigned to either an experimental group that receives the intervention being tested or a comparison/control group that receives a placebo or conventional treatment. The primary goal is to assess whether the intervention can effectively reduce and mitigate the impact of CIPN symptoms. The study aims to evaluate the feasibility and acceptability of conducting such a trial. The REACT-CIPN behavioural intervention has been co-designed and developed by patients and staff at Guy's and St. Thomas' NHS Foundation Trust (GSTFT) with the intention of providing patients with strategies for managing symptoms. The intervention is comprised of two components: a printed booklet that is given to the participant before chemotherapy starts and a short film that is delivered during or after cycle 2 of treatment.

### Who can participate?

Adult patients aged over 18 years old who have been diagnosed with breast or colorectal cancer

### What does the study involve?

This is a single-centre study that will be conducted at GSTFT. The REACT-CIPN intervention will be compared with standard care (the control condition) and patients will be randomised to either standard care and intervention or standard care alone in a 1:1 ratio. In addition, clinician participants will be recruited to explore their views about delivering the intervention or delivering CIPN information as standard care.

Clinicians involved in the delivery of REACT-CIPN intervention will receive appropriate training. Patients will be enrolled in the study for up to 12-24 weeks i.e. from the start of chemotherapy treatment until the end of treatment.

### What are the possible benefits and risks of participating?

There are no guaranteed benefits from taking part in this study. The findings are expected to

improve the experiences of patients when receiving information about their chemotherapy treatment. Although this may not benefit individuals personally, the information they give may help influence and shape practice and services in the future. The researchers do not anticipate any serious adverse events (SAEs) occurring because of study participation.

Where is the study run from?  
King's College London (UK)

When is the study starting and how long is it expected to run for?  
January 2023 to December 2023

Who is funding the study?  
King's College London (UK)

Who is the main contact?  
Mary Tanay  
mary.tanay@royalberkshire.nhs.uk

## Contact information

**Type(s)**  
Principal Investigator

**Contact name**  
Prof Glenn Robert

**ORCID ID**  
<http://orcid.org/0000-0001-8781-6675>

**Contact details**  
King's College London  
James Clerk Maxwell Building  
57 Waterloo Road  
London  
United Kingdom  
SE1 8WA  
+44 (0)207 848 3229  
glenn.robert@kcl.ac.uk

**Type(s)**  
Public

**Contact name**  
Dr Mary Tanay

**ORCID ID**  
<http://orcid.org/0000-0002-6851-9605>

**Contact details**  
King's College London  
James Clerk Maxwell Building

57 Waterloo Road  
London  
United Kingdom  
SE1 8WA  
+44 (0)207 848 3229  
mary.tanay@royalberkshire.nhs.uk

## Additional identifiers

### EudraCT/CTIS number

Nil known

### IRAS number

297838

### ClinicalTrials.gov number

Nil known

### Secondary identifying numbers

IRAS 297838, CPMS 53097

## Study information

### Scientific Title

REACT-CIPN Study: a feasibility randomised controlled trial with process evaluation of a co-designed intervention for chemotherapy-induced peripheral neuropathy

### Acronym

REACT-CIPN FRCT

### Study objectives

To evaluate study processes to determine if the design is feasible and acceptable to carry out in the chemotherapy treatment pathway.

To evaluate patient and clinician experiences and opinions of receiving and delivering the intervention to inform refinement for a definitive trial.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

Approved 14/04/2023, London-Surrey Research Ethics Committee (Nottingham Centre, The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, United Kingdom; +44 (0)207 1048 088; surrey.rec@hra.nhs.uk), ref: 23/LO/0192

### Study design

Single-centre feasibility randomized controlled trial with nested process evaluation

### Primary study design

Interventional

## **Secondary study design**

Randomised controlled trial

## **Study setting(s)**

Hospital

## **Study type(s)**

Safety, Efficacy

## **Participant information sheet**

Not available in web format, please use contact details to request a participant information sheet.

## **Health condition(s) or problem(s) studied**

Cancer (breast and colorectal)

## **Interventions**

The REACT-CIPN intervention comprises two components: (a) a printed booklet given to the participant before chemotherapy starts and (b) a short film which is provided during or after cycle 2 of treatment. Participants randomised to the intervention arm will also receive standard care.

Participants will be randomised in a 1:1 ratio to receive either REACT-CIPN + standard care (intervention group) or standard care (control group). Using the King's Clinical Trials Unit (KCTU), blocked randomisation (1:1) will be used to allocate participants between two arms: the intervention group (n = 15) and the control group (n = 15).

The clinicians will go through the booklet with the patient participant by telephone or in the clinic before they start chemotherapy. There is a section in the booklet that allows patients to write their questions and record their symptoms. The booklet is broadly divided into the following sections:

1. CIPN, symptoms and impact on physical functions
2. Self-assessment and communication of symptoms with the clinical team
3. Self-management strategies
4. Available services and support from clinicians
5. Living with CIPN

The ten-minute film, which reinforces key messages from the booklet, will be provided on or after the second cycle of chemotherapy. The film will be shown during cycle 2 if the patient wants to view it during chemotherapy treatment. As well as watching it during their infusion, the link will be sent to them by the lead researcher or another member of the research team to access at home. The film and an electronic copy of the booklet will be hosted on a virtual platform which the participants are able to access –as many times as they wish– until the end of their study participation.

Clinicians who give information about CIPN (chemotherapy unit nurses, clinical nurse specialists or pharmacists), who will be involved in delivering the REACT-CIPN intervention, will receive training that covers the theoretical basis and overview of the intervention.

## **Intervention Type**

## Behavioural

### Primary outcome measure

Feasibility outcomes will be measured using a mixed methods approach. Quantitative data regarding recruitment, adherence and attrition will be collected using a study case report form and qualitative data regarding the acceptability of the study processes and intervention will be collected via telephone interviews. These will be collated at the end of the study to assess the following components of the feasibility study:

1. Willingness of participants to be randomised
2. Number of eligible patients
3. Recruitment and retention rate
4. Reasons for refusal/withdrawal
5. Estimate effect size and sample size for a future study
6. Time needed to collect and analyse data
7. Defining the main outcome measure of the full RCT
8. Descriptive analysis of patient-reported outcome measures (PROMs) data to assess the appropriateness of PROMs i.e. item and questionnaire level of missing data, floor and ceiling effects, internal consistency etc

### Secondary outcome measures

To assess the potential efficacy in adult patients who are at risk of developing chemotherapy-induced peripheral neuropathy (CIPN). CIPN outcomes are measured using the following:

1. The EORTC quality of life (EORTC QLC CIPN20) scale at baseline, week 8 and week 12
2. The Numerical Rating Scale (NRS) at baseline, week 8 and week 12
3. The EuroQol quality of Life (EQ-5D-5L) health questionnaire
4. EQ Visual Analogue Square (EQ-VAS) at baseline, week 8 and week 12

To explore potential therapeutic mechanisms of change in relation to CIPN outcomes using the following

1. Illness perception using the Brief Illness Perception Questionnaire at baseline, week 8 and week 12
2. General self-efficacy using the General Self-Efficacy Scale at baseline, week 8 and week 12

### Overall study start date

01/01/2023

### Completion date

31/12/2023

## Eligibility

### Key inclusion criteria

Adult patients who are:

1. Able to give informed consent
2. Diagnosed with either colorectal or breast cancer
3. Due to receive their first neurotoxic chemotherapy treatment, and
4. At the risk of developing neuropathy (CIPN) due to chemotherapy such as Oxaliplatin, Docetaxel or Paclitaxel.
5. Can understand and communicate in English

Clinicians in the chemotherapy unit or outpatient clinics who provide information about CIPN will be recruited.

**Participant type(s)**

Patient, Health professional

**Age group**

Adult

**Lower age limit**

18 Years

**Upper age limit**

99 Years

**Sex**

Both

**Target number of participants**

n=30 (patients); n = up to 8 (clinicians)

**Key exclusion criteria**

Patients will be excluded if they:

1. Are unable to provide informed consent
2. Have received prior neurotoxic chemotherapy
3. Have pre-existing self-reported peripheral neuropathy due to other conditions e.g. diabetes or complication of previous surgery

**Date of first enrolment**

20/06/2023

**Date of final enrolment**

20/10/2023

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

Guy's Cancer Centre, Guy's and St. Thomas' NHS Foundation Trust (GSTFT)

Great Maze Pond

London

United Kingdom

SE1 3SS

# Sponsor information

## Organisation

King's College London

## Sponsor details

Room 8.11, 8th Floor  
Melbourne House  
44-46 Aldwych  
London  
England  
United Kingdom  
WC2B 4LL  
+44 (0)2078487306  
vpri@kcl.ac.uk

## Sponsor type

University/education

## Website

<http://www.kcl.ac.uk/index.aspx>

## ROR

<https://ror.org/0220mzb33>

# Funder(s)

## Funder type

University/education

## Funder Name

King's College London

## Alternative Name(s)

King's College, King's College London UK, KCL, King's

## Funding Body Type

Government organisation

## Funding Body Subtype

Universities (academic only)

## Location

United Kingdom

# Results and Publications

## Publication and dissemination plan

- 1. Planned publication in a high-impact peer-reviewed journal; open access
- 2. Presented widely through conference presentations, internal reports, social media and professional networks

## Intention to publish date

31/12/2024

## Individual participant data (IPD) sharing plan

### Data Storage

All participants’ personal data and non-personal research data provided will be secured for a further seven years after the end of the study and then destroyed securely, in keeping with standard research practice. Paper copies and password-protected storage devices will be securely archived for seven years through the King’s College London account with Iron Mountain and can only be accessed by the chief investigator and lead co-researcher. Data will be stored as per Data Protection Act (2018) and King's College London Data Management Policy and Guidelines which may be found on: <https://www.kcl.ac.uk/governancezone/Research/Research-Data-Management-Policy.aspx>; <https://www.kcl.ac.uk/library/researchsupport/research-data-management/index.aspx>

## IPD sharing plan summary

Stored in non-publicly available repository

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			20/09/2023	No	No